Phase I/II – First Administration

443 trials 187 recruiting

Filter these 443 trials by condition, country, sponsor and more.

Open in Search →

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma Recruiting

2024-511454-45-00 Relapsed or Refractory Multiple Myeloma 2020-11-09
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination with Cemiplimab in Adult Patients with Recurrent Ovarian Cancer or Other… Recruiting

2024-510783-23-00 Fallopian Tube Cancer 2020-10-29
Treatment of patients with solid tumors with genetically modified patients' own T-cells, recognizing a particular tumor marker Recruiting

2024-515114-41-00 Solid tumors 2020-08-10
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to… Recruiting

2023-509847-29-00 Advanced solid tumors 2020-04-09
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1… Recruiting

2024-515504-39-00 Patients with hematological malignancies (Cf. inclusion 2020-02-09
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-00… Recruiting

2024-512606-25-00 Advanced Solid Tumors 2019-12-20
A phase I/II trial of TG4050, an individualised gene therapy, in patients with advanced cancer of the head and neck. Recruiting

2023-508561-33-00 Newly diagnosed, stage III or IV amenable to surgery, H 2019-12-12
First in human study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with… Recruiting

2024-512894-29-00 Prostate Cancer 2019-11-15
Tissue replacement in RPE related dystrophies Recruiting

2024-513662-18-00 Patients with retinitis pigmentosa due to monogenic mut 2019-08-19
Gene Therapy for Crigler-Najjar Syndrome Recruiting

2023-507007-60-00 severe Crigler-Najjar syndrome in patients requiring ph 2018-04-09
Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid … Recruiting

2024-513627-16-01 Colorectal cancer metastatic 2018-03-28
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA Recruiting

2023-510032-37-00 Mucopolysaccharidosis type IIIA 2017-04-18
A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent … Recruiting

2023-505625-14-00 Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r 2017-01-31
An open-label study to investigate ECUR-506 in male children less than 9 months of age with neonatal onset OTC deficiency Ended

2023-506180-34-01 Ornithine Transcarbamylase Deficiency (OTC) 2026-04-10
A Phase 1/2 Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM Ended

2024-519005-35-00 Type 2 Diabetes Mellitus 2026-03-09
A Phase 1/2a Study of UCART22 in B-cell Acute Lymphoblastic Leukemia (BALLI-01) Ended

2022-502305-15-00 Relapsed or refractory B-cell Acute Lymphoblastic Leuk 2025-11-26
A study of S095035 as a single agent and in combination in adult participants with advanced or metastatic solid tumors with deletion of MTAP Ended

2025-521249-25-00 MTAP-deleted advanced or metastatic solid tumors 2025-10-30
An interventional, multicenter, and international phase 1/2, light-dose-escalation study to investigate the safety and feasibility of intrao… Ended

2025-520563-41-00 High-grade glioma Glioblastoma 2025-09-29
A study on the safety, and immunogenicity of a UTI vaccine in adults 18 through 64 years of age and clinical efficacy in females 18 through … Ended

2024-519319-32-00 Urinary Tract Infections 2025-08-27
FTIH study to investigate the safety and preliminary efficacy of the DNA-repair inhibitor GSK4418959 alone or in combination with other anti… Ended

2024-519721-37-00 Neoplasms, Colorectal 2025-08-06
First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended

2023-506842-22-00 Recurrent endometrial cancer, recurrent epithelial ovar 2025-05-19
Phase I/II study of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma Ended

2024-517114-15-00 newly diagnosed gliblastoma 2025-03-07
Safety and efficacy of the FTP-002 / FTP-501 combination in the treatment of glabellar lines. Ended

2023-507249-27-00 glabellar lines. 2024-11-26
Study of JDQ443 in advanced cancer with a specific mutation (G12C) of the KRAS gene Ended

2023-508073-87-00 Advance solid tumors harboring the KRAS G12C mutation 2024-11-14